High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations
Authors
Ceccherini Silberstein, Francesca; Gago Badenas, FedericoIdentifiers
Permanent link (URI): http://hdl.handle.net/10017/5122DOI: 10.1128/JVI.79.16.10718-10729.2005
Publisher
American Society for Microbiology
Date
2005Bibliographic citation
JOURNAL OF VIROLOGY, Aug. 2005, p. 10718-10729
Document type
info:eu-repo/semantics/article
Version
info:eu-repo/semantics/publishedVersion
Publisher's version
http://dx.doi.org/10.1128/JVI.79.16.10718-10729.2005Access rights
info:eu-repo/semantics/openAccess
Abstract
To define the extent of sequence conservation in human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) in vivo, the first 320 amino acids of RT obtained from 2,236 plasma-derived samples from
a well-defined cohort of 1,704 HIV-1-infected individuals (457 drug na¿¿ve and 1,247 drug treated) were analyzed
and examined in structural terms. In na¿¿ve patients, 233 out of these 320 residues (73%) were conserved (<1%
variability). The majority of invariant amino acids clustered into defined regions comprising between 5 and 29
consecutive residues. Of the nine longest invariant regions identified, some contained residues and domains
critical for enzyme stability and function. In patients treated with RT inhibitors, despite profound drug
pressure and the appearance of mutations primarily associated with resistance, 202 amino acids (63%)
remained highly conserved and appeared mostly distributed in regions of variable length. This finding suggests
that participation of consecutive residues in structural domains is strictly required for cooperative functions
and sustainability of HIV-1 RT activity. Besides confirming the conservation of amino acids that are already
known to be important for catalytic activity, stability of the heterodimer interface, and/or primer/template
binding, the other 62 new invariable residues are now identified and mapped onto the three-dimensional
structure of the enzyme. This new knowledge could be of help in the structure-based design of novel resistanceevading
drugs.
Collections
- FARMACOL - Artículos [13]